# AVASTIN (bevacizumab) - DailyMed Prescribing Information

**Source**: DailyMed - NIH U.S. National Library of Medicine
**Document ID**: setid=939b5d1f-9fb2-4499-80ef-0607aa6b114e
**Retrieved**: September 2024

## INDICATIONS AND USAGE

### Recurrent Glioblastoma (rGBM)
AVASTIN is indicated for the treatment of recurrent glioblastoma (GBM) in adults.

## DOSAGE AND ADMINISTRATION

### For Recurrent Glioblastoma
- **Dose**: 10 mg/kg intravenously 
- **Schedule**: Every 2 weeks
- **Duration**: Continue treatment until disease progression or unacceptable toxicity

### Administration Protocol
- **Route**: Intravenous infusion only (DO NOT administer as IV push or bolus)
- **First infusion**: 90 minutes
- **Second infusion**: 60 minutes (if first infusion tolerated)
- **Subsequent infusions**: 30 minutes (if previous infusions tolerated)

### Dose Modifications
- **No dose reductions are recommended**
- **Management approach**: Temporarily withhold or permanently discontinue for adverse reactions

## CONTRAINDICATIONS
None specified in prescribing information.

## WARNINGS AND PRECAUTIONS

### Gastrointestinal Perforation
- Serious and sometimes fatal gastrointestinal perforation can occur
- Monitor patients for signs and symptoms
- Permanently discontinue for gastrointestinal perforation

### Surgery and Wound Healing Complications
- Impairs wound healing
- Withhold AVASTIN for at least 28 days prior to elective surgery
- Do not initiate AVASTIN for at least 28 days after surgery and until wound is fully healed

### Hemorrhage
- Severe or fatal hemorrhage can occur
- Monitor for signs and symptoms of bleeding
- Permanently discontinue for Grade 3-4 hemorrhage

### Arterial Thromboembolic Events
- Increased risk of arterial thromboembolic events
- Permanently discontinue for arterial thromboembolic events

### Hypertension
- Monitor blood pressure every 2-3 weeks
- Treat with appropriate antihypertensive therapy
- Temporarily suspend for severe hypertension

### Posterior Reversible Encephalopathy Syndrome (PRES)
- Rare neurological disorder
- Confirm diagnosis with MRI
- Discontinue AVASTIN

### Renal Injury and Proteinuria
- Monitor for proteinuria
- Suspend treatment for nephrotic syndrome
- Permanently discontinue for thrombotic microangiopathy

### Infusion-Related Reactions
- Monitor during infusion
- Interrupt infusion for severe reactions
- Provide appropriate medical management

## ADVERSE REACTIONS

### Most Common Adverse Reactions (>10%) in rGBM Studies
- Epistaxis (nosebleeds)
- Headache
- Hypertension
- Proteinuria
- Hemorrhage

### Serious Adverse Reactions
- In clinical studies for recurrent glioblastoma, 22% of patients discontinued treatment due to adverse reactions
- Adverse reaction profile similar to other approved indications

### Grade 3-4 Adverse Events
- Fatigue
- Hypertension
- Convulsion/seizures
- Headache

## FDA APPROVAL HISTORY

### Initial Approval
- **Date**: May 5, 2009 (Accelerated approval)
- **Basis**: Single-arm studies showing objective response rates

### Regular Approval
- **Date**: December 5, 2017
- **Basis**: Confirmatory randomized controlled trial

### Clinical Evidence
- **Response Rate**: 25.9% (95% CI: 17.0%-36.1%) in pivotal trial
- **Patient Population**: All patients had received prior surgery, radiotherapy, and temozolomide
- **Exclusions**: Patients with active brain hemorrhage were excluded

## DRUG INTERACTIONS
- **Potential interactions**: Monitor when used with other antineoplastic agents
- **No specific drug interactions listed** for glioblastoma indication

## USE IN SPECIFIC POPULATIONS

### Pregnancy
- **Category**: May cause fetal harm
- **Recommendation**: Advise females of reproductive potential to use effective contraception during treatment and for 6 months after last dose

### Lactation
- **Recommendation**: Advise against breastfeeding during treatment and for 6 months after last dose

### Pediatric Use
- Safety and effectiveness not established in pediatric patients

### Geriatric Use
- No overall differences in safety observed
- Monitor closely for adverse reactions

## OVERDOSAGE
- No information available on overdosage
- In case of overdosage, monitor closely for adverse reactions

## CLINICAL PHARMACOLOGY

### Mechanism of Action
- Humanized monoclonal antibody
- Binds and inhibits vascular endothelial growth factor A (VEGF-A)
- Prevents interaction with VEGF receptors on endothelial cells

### Pharmacokinetics
- **Half-life**: Approximately 20 days (range 11-50 days)
- **Clearance**: 0.207-0.262 mL/day/kg
- **Volume of distribution**: 2.73-3.25 L

## NCCN GUIDELINE INCLUSION
Bevacizumab as a single agent or in combination with chemotherapy is included in NCCN recommendations for recurrent glioblastoma.

## STORAGE AND HANDLING
- **Storage**: Refrigerate at 36째F to 46째F (2째C to 8째C)
- **Protect from light**
- **Do not freeze or shake**
- **Single-use vial**: Discard unused portion

## MANUFACTURER INFORMATION
- **Manufacturer**: Genentech, Inc.
- **FDA Application Number**: BLA 125085

*This document contains the essential prescribing information from DailyMed for bevacizumab (AVASTIN) specifically for recurrent glioblastoma treatment.*